Navigation Links
Golimumab Eases Rheumatoid Arthritis Symptoms
Date:6/11/2008

Monthly shot plus weekly methotrexate even pushed some into remission, study says

WEDNESDAY, June 11 (HealthDay News) -- Adding monthly injections of golimumab to weekly doses of methotrexate helped most people with rheumatoid arthritis, even putting some into remission, two new studies show.

The findings on golimumab, an anti-tumor necrosis factor (TNF)-alpha biologic therapy drug, were scheduled to be presented Tuesday at the European League Against Rheumatism Annual Congress of Rheumatology, in Paris.

In the first study, one group of patients taking methotrexate weekly for active rheumatoid arthritis were given either 50-milligram or 100-milligram doses of golimumab via subcutaneous injections, while the rest of the patients received a placebo and methotrexate.

After just 14 weeks, 35 percent of those receiving 50-milligram doses of golimumab and 32 percent of patients in the 100-milligram group achieved remission as measured by Disease Activity Score. Only 13 percent in the placebo group reached remission. These improvements were sustained for six months.

More than two-thirds of the golimumab patients increased their ability to perform routine activities such as arising, dressing, eating, walking, hygiene, reaching and gripping after 24 weeks on the additional drug. Some of the improvements were noticeable after four weeks of the first golimumab injection, and the golimumab patients generally continued to improve over the duration of the study.

Only 39 percent of those in the placebo group showed similar improvement after 24 weeks.

"The data in this study demonstrate that golimumab is beneficial in improving numerous disease parameters, including inducing remission, in patients whose disease was active despite ongoing treatment with methotrexate," lead investigator Dr. Edward Keystone, director of the Rebecca MacDonald Centre for Arthritis and Autoimmune Disease at Mount Sinai Hospital in Toronto, said in prepared statement. "Since some patients do not respond adequately to methotrexate alone, this combination therapy could prove to be a highly valuable treatment option based on these results."

In the second study, rheumatoid arthritis patients who had never taken methotrexate were treated with that drug and either 50 milligrams or 100 milligrams of golimumab. These patients also experienced a lessening of the signs and symptoms of arthritis as well as in disease activity, with 38 percent of those receiving the two drugs experiencing a 50 percent drop in signs and symptoms of RA after 24 weeks. Just 29 percent of those receiving a placebo plus methotrexate experienced a similar improvement in their condition.

Thirty-eight percent of patients receiving golimumab meet the remission standard after 24 weeks.

"These data show that treatment with golimumab induces an important depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in disease activity," study investigator Dr. Roy Fleischmann, chief of the rheumatology division at St. Paul University Hospital in Dallas, said in a prepared statement. "Golimumab is a promising treatment option for multiple patient populations with this chronic and potentially debilitating inflammatory disease."

More information

The U.S. National Library of Medicine has more about rheumatoid arthritis.



-- Kevin McKeever



SOURCE: Centocor Inc., news release, June 10, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Adding Light Eases Behavioral Problems of Dementia
3. Los Angeles Jewish Home Increases Resident Capacity and Adds New Programs to Address Community Needs
4. Fitness Anywhere, Maker of the TRX Suspension Trainer(TM), Releases Two New Specialized Training Programs
5. Cancer incidence and mortality in young people decreases with increasing deprivation
6. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
7. The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere
8. Teen Sexual Activity Increases, Contraceptive Use Decreases
9. Metformin increases pathologic complete response rates in breast cancer patients with diabetes
10. Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care
11. Acupuncture Eases Side Effects of Head, Neck Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: